EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center

Qianqian Mao iD, Zhenping Chen, Guoqing Liu, Gang Li, Yingzi Zhen, Xiaoling Cheng iD, Zekun Li, Wanru Yao, Di Ai, Zhengping Li iD, Nan Wang iD, Man-Chiu Poon iD und 1 weitere

Pediatric Investigation · 2024

DOI: 10.1002/ped4.12439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Investigation, 2024. Verfasst von Qianqian Mao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hemophilia Comprehensive Care Center, Hematology Center, Beijing Key Laboratory of Pediatric Hematology-Oncology, Key Laborato…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China.

Objective

To explore the possibility of using reduced‐dosage EMI in Chinese HA children.

Methods

We conducted a retrospective study for HA children in our Comprehensive Care Center. Data were collected pre‐ and post‐EMI treatment to evaluate bleeding rates. Laboratory analyses included factor VIII (FVIII)‐like activity and EMI concentration measurements.

Results

Thirty‐four HA children receiving EMI prophylaxis for a median (range) 24.5 (2.5–47.9) months by June 2023. Of these, 25 (73.5%) were under 3 years of age, 26 (76.5%) had severe hemophilia and 12 (35.3%) were minimally treated or previously untreated patients. Thirty‐one (91.2%) of the 34 patients received reduced‐dosage EMI for economic reasons. EMI concentration and FVIII‐like activity measured showed a strong correlation. Overall, while on EMI, their annual treated bleeding rate (ATBR) and annual bleeding rate (ABR) decreased significantly (2–0) while their zero‐bleeding rate (ZBR) increased significantly (11.5%–65.4%). After 6 months of EMI, there was no significant difference in ATBR and ABR among various maintenance dosages. However, ZBR was significantly lower in dosages under 4 mg/kg ( P = 0.0156). Receiver operator characteristic curves suggested the following cutoff values for zero bleeding: EMI 4‐weekly maintenance dosage 3.8 mg/kg, EMI concentration 48.1 μg/mL, and FVIII‐like activity 15.4 IU/dL.

Interpretation

We showed EMI effectively prevented bleeding even at reduced dosages. However, the bleeding risk may be higher with EMI 4‐weekly maintenance dosage

Schlagwörter

Stichwörter der Autor:innen

EmicizumabHemophilia AProphylaxis

Autor:innen und Institutionen

  • Hematology Department, Hemophilia Comprehensive Care Center, Hematology Center, Beijing Key Laboratory of Pediatric Hematology-Oncology, Key Laboratory of Major Diseases in Children, National Center for Children's Healt…
  • Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology-Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Nati…
  • Department of Pharmacy Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China.
  • Departments of Medicine, Foothills Medical Centre University of Calgary 1403-29th Street NW Calgary T2N 2T9 Alberta Canada.

ORCID-Profile: Qianqian Mao, Xiaoling Cheng, Zhengping Li, Nan Wang, Man-Chiu Poon, Runhui Wu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, Q., Chen, Z., Liu, G., Li, G., Zhen, Y., Cheng, X., Li, Z., Yao, W., Ai, D., Li, Z., Wang, N., Poon, M. C., & Wu, R. (2024). Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center. Pediatric Investigation. https://doi.org/10.1002/ped4.12439

Vancouver

Mao Q, Chen Z, Liu G, Li G, Zhen Y, Cheng X, et al. Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center. Pediatric Investigation. 2024. doi:10.1002/ped4.12439

BibTeX
@article{Mao2024,
  author = {Mao, Qianqian and Chen, Zhenping and Liu, Guoqing and Li, Gang and Zhen, Yingzi and Cheng, Xiaoling and Li, Zekun and Yao, Wanru and Ai, Di and Li, Zhengping and Wang, Nan and Poon, Man-Chiu and Wu, Runhui},
  title = {Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center},
  journal = {Pediatric Investigation},
  year = {2024},
  doi = {10.1002/ped4.12439}
}
Kostenlos starten →